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Background: Extracts from the bark of Hintonia latiflora are used as dietetic measures to support the regulation of
glucose metabolism and the stabilization of blood glucose values.
Methods: A dry concentrated extract from the bark of Hintonia latiflora in capsule form was tested in an open,
prospective clinical study in 41 dietetically stabilized subjects with type 2 diabetes. The effects on parameters of
blood glucose control were documented over a period of six months.
Results: Fasting and postprandial glucose and the HbA1c value declined significantly. In the case of HbA1c, this
meant a reduction of the absolute value from 7.49 ± 0.72% to 6.82 ± 0.67% (from 58.4 to 51.0 mmol/mol Hb;
intention to treat (ITT) population). Furthermore, cholesterol and triglycerides were slightly reduced and no negative
effect on other laboratory parameters and no change of the liver values were observed. Tolerance was very good.
In particular, no side effects and no hypoglycemic episodes or worsening of diabetic symptoms occurred.
Conclusions: The study confirms the positive effect of extracts from the bark of Hintonia latiflora on blood glucose
values suggesting a potential benefit in the management of glucose metabolism in cases of type 2 diabetes.
Trial registration: Reg.-No. ISRCTN83308122
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Positive effects of preparations of the bark of the Central
American plant Hintonia latiflora (family Rubiaceae) on
blood glucose reduction and therefore the maintenance
of physiologically normal blood glucose values have been
reported in scientific investigations published over at
least the past 60 years [1-8]. Normalizations of diabetic
parameters, with the absence of hypoglycemic episodes,
have been observed upon exposure to Hintonia extracts
[9-13]. In a long-term study lasting up to 33 months, the
mean HbA1c value of the participants decreased below
the target value of 7% after six months of consumption
of a liquid extract from the bark of Hintonia latiflora,
with excellent tolerance [14].* Correspondence: statistika.hladikova@seznam.cz
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article, unless otherwise stated.The basic hypothesis of the present six-month open,
prospective study was that the previously observed anti-
diabetic effects can be achieved with an alternative prep-
aration of the Hintonia extract in the form of capsules
from a dry concentrate. The selected dose scheme corre-
sponded to the patient exposure in the previous study. It
was known to be safe from more than 30 years of clin-
ical experience with the liquid formulation, and from the
mentioned bibliographic sources. Safety in the relevant
dose range has also been established through animal
studies with chronic exposure [4].Methods
Study design and test preparation
The study was designed as a six-month, prospective
open prospective clinical study. It was based on the eth-
ical principles of the Declaration of Helsinki/Somerset
West and registered with ISRCTN (register numbered Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Demographic and anamnestic patient data
Number of patients n = 41 (100%)
Female n = 33 (80.5%)
Male n = 8 (19.5%)
Age 60.9 ± 8.5 years
Age range 41 to 79 years
Duration of the diabetes symptoms 5.9 ± 4.9 years
Range for duration of the diabetes symptoms 1 to 19 years
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quired from the study participants.
The test preparation of this study (Sucontral™ D Cap-
sules, Harras Pharma Curarina, Munich, Germany) con-
tained 100 mg of a dry concentrate per capsule (extraction
solvent ethanol 32%; DERfinal 2.4:1) from the bark of the
Central American plant Hintonia latiflora (SESSÉ & MOC.
ex DC.) BULLOCK (Rubiaceae). The plant material was
from a controlled collection. The extract was prepared
under good manufacturing practice (GMP) conditions
and tested against a predefined analytical specification
including tests for heavy metals, aflatoxins, pesticides
and microbiology as well as an assay on polyphenol con-
tent (6 to 10%, calculated as coutareagenin). Per capsule,
24 mg polyphenols were supplied. The capsules also
contained 30 mg vitamin C, 5 mg vitamin E, 0.7 mg
vitamin B1, 0.8 mg vitamin B2, 1 mg vitamin B6, 0.5 μg
vitamin B12, 100 μg folic acid, 75 μg biotin, 2.5 mg zinc
and 25 μg chromium. In accordance with the recom-
mended intake, patients took one capsule before meals
twice daily while adhering to a prescribed diet.
Both the stabilization of the study participants to con-
stant HbA1c values, and the testing of diabetic parameters
took place in the study center. Only subjects suffering from
type 2 diabetes in the age range of 45 to 80 years, taking
neither oral antidiabetic agents nor insulin, were eligible as
participants. All participants followed a dietary regime,
which led to stable, but not normoglycemic values.
For inclusion in the study, diabetic symptoms must have
existed for a period of at least 12 months. The values for
fasting blood glucose were to be in the range of 7 to
14 mmol/l (normal value: 3.9 to 5.4 mmol/l).
Doubts regarding the reliability of a potential partici-
pant with respect to the adherence to the dietetic regime
(for example, with respect to alcohol consumption) were
defined as an exclusion criterion. Other reasons for ex-
clusion were severe diabetic symptoms, progressive life-
threatening diseases, hepatic dysfunction or renal insuffi-
ciency (deviations of GOT, γGT and AP of more than
twice the normal value, serum creatinine >130 μmol/l),
hypoglycemic crises not noticed in time, retinopathy,
pregnancy, malignant tumors and/or drug or alcohol de-
pendence in the patient’s medical history.
The dietary measures continued unchanged over the
entire course of the study to exclude a distorting influ-
ence of nutrition on the study results confirming the at-
tribution of changes of the diabetic parameters to the
tested preparation containing a dry concentrate from
Hintonia bark.
Anamnestic and demographic data, diabetic parameters
and liver values were collected at the start of the study.
Fasting and postprandial blood glucose (two hours after
food intake), blood pressure and body weight were re-
corded at monthly intervals. Indications of improvementsor deteriorations of the diabetic symptoms (neuropathy,
paraesthesia, constipation and sweating) were likewise
documented at monthly intervals. The HbA1c value, liver
function tests and blood lipids were recorded at three and
six months.
Biometric analysis
Statistical differences were assessed by ANOVA tests for
repeated measurements. The statistical software package
was SPSS version 20, release 20.0.0.
The statistical significance values were calculated both
on the ‘per protocol’ population (PP, all participants who
completed the study as planned) and the ‘intention to
treat’ population (ITT; with the last measured value car-
ried over in cases of lacking data).
Results
The demographic data of the patients is presented in
Table 1. Forty-one participants were included in the study.
Nine of the participants (two men and seven women) pre-
maturely terminated their participation in the study:
1) at the participant’s request in four cases (two after
one month, and two after three months); 2) on recom-
mendation of the physician in four cases due to unreli-
ability of the participant with respect to compliance with
the dietary measures: (two after one month, and one
after two and three months, respectively); and 3) in one
case because of an acute infection from a concomitant
disease.
All nine participants had shown improvements of the
diabetic parameters at the time of withdrawal. This in-
cluded HbA1c values for all dropouts with a minimum
study duration of three months.
The size of the ITT population was n = 41, and that of
the PP population was n = 32 participants.
Effect on diabetes parameters
The results of the statistical analysis differed only slightly
for the ITT and PP population. For both analyses, there
was a statistically significant difference compared with
the starting values for all time points where measure-
ments were made (P <0.001 in all individual cases).
The average HbA1c value at the start of the study was
7.49 ± 0.72% (58.36 mmol/mol Hb). Within the six
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8.95% (ITT population) and 11.2% (PP). In absolute
values, this corresponded to a decrease by 0.67%
(7.32 mmol/mol Hb) in the ITT group to a final value of
6.82 ± 0.67% (51.04 mmol/mol Hb), and of 0.84%
(9.18 mmol/mol Hb) in the PP population to a final
value of 6.65 ± 0.58% (49.18 mmol/mol Hb). The target
value of 7% (53 mmol/mol Hb) as predefined upper limit
for clinical relevance was therefore reached (Figure 1).
Similar results were found for fasting and postprandial
glucose; again, the six-month exposure resulted in a sta-
tistically significant reduction of blood glucose over
starting values, with a continuous improvement of
values at every monthly measurement. Both, the ITT
and the PP analysis yielded practically identical results
with a 25% reduction of starting values of fasting blood
glucose (from 8.0 ± 1.0 to 6.0 ± 0.6 mmol/l in both
groups), and a 22% lowering of the postprandial glucose
(from 10.2 ± 1.4 to 8.0 ± 6.7 mmol/l) (Figure 2).
Liver parameters and blood lipids
The laboratory parameters were only considered in the
ITT analysis. All parameters remained uninfluenced,
with the exception of a slight improvement of the values
of the transaminases ALT and GGT. This improvement
was found to be statistically significant, but not clinically
relevant; the value of alanine aminotransferase ALT de-
creased from 0.41 ± 0.10 U/l to 0.36 ± 0.07 U/l, and that
of glutamyl aminotransferase from 0.45 ± 0.29 U/l to
0.36 ± 0.17 U/l. However, the starting values were already
clearly within the ‘healthy’ range (0 to 35 U/l). Other liver
values and clinical laboratory tests such as alkaline phos-
phatase, aspartate aminotransferase, bilirubin or creatine
kinase remained unchanged. For the blood lipids, whichFigure 1 Course of HbA1c values under intake of Hintonia extract. Cou
All measured values were statistically significant compared with the startingwere found to be elevated at the start of the study, a slight
but clinically marginally relevant decrease was noted;
cholesterol decreased from 213.5 ± 34.0 mg/dl to 202.6 ±
32.9 mg/dl (p = 0.026), and triglycerides from 193.1 ±
87.7 mg/dl to 164.8 ± 59.3 mg/dl. Other parameters such
as LDL and HDL showed no change.
Discussion
The three crucial glycemic parameters, HbA1c, fasting and
postprandial glucose, were statistically significantly and
clinically reduced during intake of a dry concentrate from
the bark of Hintonia latiflora. Published studies suggest a
risk reduction of diabetic macro- and microangiopathies
with an improvement of glycemic parameters [15,16].
The so-called ‘ADVANCE’ study observed a positive ef-
fect of an improved control of HbA1c on risk factors of
diabetes mellitus through the application of oral antidia-
betics [17]. In parallel, there was another large study
commonly designated as the ‘ACCORD’ trial, where sur-
prisingly, an aggressive lowering of HbA1c by a combin-
ation of antidiabetic medications was associated with an
increased long-term mortality [18]. It has been suggested
that this seemingly paradoxical finding might have been
caused by pre-existing cardiovascular risk factors in pa-
tients with insufficiently controlled long-term diabetes,
by adverse effects of the medication, and, last but not
least, by hypoglycemic episodes triggered by the study
medication(s) [19,20]. Clearly the debate around the two
studies shows that measures for an early improvement of
glycemic control and homeostasis are warranted, espe-
cially if they are not associated with a risk of hypoglycemic
episodes. Hintonia bark extract is allocated to the context
of basic measures. According to its clinical characteristics
known from case reports and clinical observations Hintoniarse of HbA1c values in patients during treatment with Hintonia extract.
value (P <0.001).
Figure 2 Course of fasting glucose and postprandial blood glucose under intake of Hintonia extract. Course of fasting glucose (squares)
and postprandial blood glucose (circles) in patients during treatment with Hintonia extract. All measured values were statistically significant
compared with the starting value (P <0.001).
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quirement of therapy with oral antidiabetics, or even con-
tribute to a reduction of the dose of the antidiabetic
medication. Both may be considered a positive effect in the
light of the ADVANCE and ACCORD studies, although
the latter point has not been explicitly examined in this
study.
The lack of a control group could be questioned with re-
spect to the study design. In the case of diabetes mellitus,
however, placebo effects do not play a role in the long-
term application, and the measured laboratory values are
objective parameters. Untreated type 2 diabetes is typically
a progressive disease without a tendency to spontaneous
improvements. In long-term studies with oral antidia-
betics, the HbA1c value remained unchanged in the pla-
cebo group, or even showed an increase [21-23]. In the
‘United Kingdom Prospective Diabetes Study’, the HbA1c
value remained stable under the diet only during the first
year, and subsequently worsened continually. With se-
verely overweight patients, the HbA1c values increased
from the start in spite of the diet [24]. A recently pub-
lished long-term lifestyle intervention examined the ef-
fects of decreased caloric intake on the cardiovascular
risk of obese patients with type 2 diabetes. Again, the
laboratory results for glycated hemoglobin slowly in-
creased over time in the control group despite a small
loss in body weight, whereas the initial improvement in
the intervention group was almost lost with a re-increase
of body weight [25].
The results of these studies confirm that placebo ef-
fects under treatment with antidiabetic agents would not
be expected, which justifies an open trial design for stud-
ies examining the potential of an intervention.The participants of the present study were initially treated
with dietary measures until no more improvement of
HbA1c was achieved. The starting values at the beginning
of the study were the result of a dietary adjustment. This
dietary regimen was consistently complied with. The diet-
ary measures alone were insufficient to achieve approxi-
mately normoglycemic values, the values were, however,
not sufficiently elevated as to justify an intervention with
blood glucose lowering drugs such as insulin or oral antidi-
abetics. As the diet was continued unchanged during the
entire study, and therefore did not represent a variable, the
reduction of the diabetic parameters were not attributable
to nutritional effects, but rather the result of the intake of
the study preparation. The measurement of objective pa-
rameters without the explicit use of a control group there-
fore allows drawing valid assertions regarding the effects of
the test preparation.
The test preparation was a dry concentrate from the
bark of Hintonia latiflora, with a supplement of vita-
mins and trace elements that in turn can also play a
role in the carbohydrate metabolism. Consequently,
the question could be raised whether these additional
substances may have contributed to the study result. A
slight supplementary effect on blood glucose balance
must in fact be expected from the administration of vi-
tamins, and above all from trace elements such as
chromium. However, the extent of the observed im-
provement is unlikely to be reached by vitamins and
trace elements alone. A comparable effect was previ-
ously achieved with the long-term administration of
extract from the bark of Hintonia latiflora in human
beings without the addition of other micronutrients
[14], which confirms the nutritional physiological
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effects on the regulation of the blood glucose balance
could also be experimentally verified and attributed to the
polyphenolic fraction [8].
Conclusions
The intake of a neoflavonoid-containing dry concentrate
from the bark of Hintonia latiflora improved the parame-
ters of blood glucose control in type 2 diabetes mellitus.
The tolerance was excellent, and liver and lipid values
tended to be positively affected.
The observations of this study are consistent with ear-
lier studies, and specifically with a controlled long-term
study. The use of Hintonia dry extract in the dietetic
treatment of disturbances of glucose balance in cases of
mildly to moderately severe type 2 diabetes can accor-
dingly be regarded as safe and useful in those cases,
where an adequate control of the blood glucose balance
cannot be achieved with dietary measures alone.
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